University of Alabama at Birmingham Medical Center
Birmingham, Alabama, 35294, United States
Location contact
Steve Fox, MD
PRINCIPAL_INVESTIGATOR
Timothy I Kennell, MD, PhD
CONTACT
Timothy I Kennell, MD, PhD
SUB_INVESTIGATOR
NCT Number: NCT07291778
This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Birmingham, Alabama, 35294, United States
Steve Fox, MD
PRINCIPAL_INVESTIGATOR
Timothy I Kennell, MD, PhD
CONTACT
Timothy I Kennell, MD, PhD
SUB_INVESTIGATOR
This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.
Informed Arm: The treating team receives the patient's VExUS results and management recommendations.
Not-Informed Arm: The treating team remains blinded to all VExUS findings and receives no feedback or recommendations.
Each enrolled patient will undergo two VExUS ultrasound assessments:
Timepoint 1 (enrollment): Two scans are performed by separate operators to assess waveform reliability and inter-user reproducibility.
Timepoint 2 (48-72 hours after enrollment): A single scan is performed along with concurrent collection of serum creatinine, intake/output (I&O) balance, and renal replacement therapy (RRT) status.
Each VExUS exam includes Doppler evaluation of the inferior vena cava, hepatic vein, portal vein, renal cortical artery, and renal cortical vein. Scans are saved to secure UAB SharePoint storage labeled with an auto-incrementing study ID.
Blinding Procedures
To maintain study integrity and minimize bias, multiple layers of blinding will be employed:
Scanner Blinding: Sonographers performing the VExUS scans are blinded to the patient's randomization status and to all prior scan results. They collect and upload de-identified images labeled only by study ID.
Interpreter Blinding: The attending physician interpreting the scans (the "overreader") is blinded to randomization status during the image interpretation phase. The overreader reviews both scans for quality and assigns a VExUS score (0-3) before randomization status is revealed.
Recruiter/Coordinator Role: The research coordinator (unblinded) maintains the randomization list and is responsible for communicating the overread results to the treating team only for patients in the informed arm.
Primary Team Blinding: For patients in the not-informed arm, the primary clinical team will not receive any VExUS scores or recommendations, and no study-related documentation will be visible in the electronic health record (EHR).
Statistical Blinding: Data analysts will remain blinded to treatment arm allocation until after all primary outcomes are recorded.
Communication and Clinical Guidance
For patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score:
VExUS = 0: Recommend a net positive fluid balance.
VExUS = 1: Recommend a net neutral fluid balance.
VExUS >= 2: Recommend a net negative fluid balance.
These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team.
Data Management and Analysis
Two linked data lists will be maintained:
Master List (PHI-protected): Contains patient identifiers and MRNs, stored on a secure UAB server.
Patient Data List (de-identified): Contains study ID, randomization arm, scan quality, interpreter scores, creatinine values, I&O data, RRT status, ICU-free days, hospital-free days, and mortality.
All ultrasound procedures are noninvasive and adhere to ACEP emergency ultrasound standards. Protected health information will remain secured on institutional servers, and only de-identified data will be used for analysis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score:
VExUS = 0: Recommend a net positive fluid balance.
VExUS = 1: Recommend a net neutral fluid balance.
VExUS >= 2: Recommend a net negative fluid balance.
These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team.
Primary team will not be informed about the patient's VExUS score and will not be given recommendations for fluid management
Time frame: up to 30 days
In-hospital mortality: Death from any cause before hospital discharge, within the 30-day window.
Time frame: up to 30 days
New receipt of Renal Replacement Therapy (RRT): Receiving dialysis or another form of RRT for the first time.
Time frame: up to 30 days
Persistent renal dysfunction: The final serum creatinine value before hospital discharge (within 30 days) is 200% (twice) or more of the patient's baseline creatinine value.
Contact information is provided by the study sponsor or research team.
Steve Fox, MD
CONTACT
Timothy I Kennell, MD, PhD
CONTACT
University of Alabama at Birmingham
Other
The Impact of VeXUS-guided Fluid Management in ICU Populations on Renal Function
Acronym: DECONGEST-AKI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07258875
Acute Kidney Injury, Female Urogenital Diseases
Heraklion, Crete, Greece
View Trial DetailsNCT06889116
Acute Kidney Injury, Female Urogenital Diseases
Mahārājgañj, Bagmati, Nepal
View Trial DetailsNCT07719569
Acute Kidney Injury, Female Urogenital Diseases
Wolverhampton, West Midlands, United Kingdom
View Trial DetailsNCT07718373
Acute Kidney Injury, Female Urogenital Diseases
View Trial Details